Miv-cel Responses Persist at One Year

Company Kyverna Therapeutics Event Type Clinical Trial Durability Data Modality CAR-T Cell Therapy (CD19-Directed) Asset Mivocabtagene Autoleucel (Miv-cel) Target CD19 Disease Area Stiff Person Syndrome / Generalized Myasthenia Gravis Summary Kyverna reported 12-month durability from the 26-patient KYSA-8 registrational study in stiff person syndrome and…